Prognostic significance of the systemic inflammation response index in gastrointestinal malignancy patients: a pooled analysis of 10,091 participants

Future Oncol. 2023 Sep;19(29):1961-1972. doi: 10.2217/fon-2023-0545. Epub 2023 Oct 6.

Abstract

Background: We performed a meta-analysis to investigate the association of the systemic inflammation response index (SIRI) with long-term survival outcomes in patients with gastrointestinal malignancy. Methods: PubMed, Web of Science and Embase were searched for relevant studies evaluating the prognostic significance of the SIRI in gastrointestinal malignancies until May 2023. Results: 30 studies with 10,091 patients were included. The pooled results identified that patients in the high SIRI group had a worse overall survival and disease-free survival, which was observed across various tumor types, tumor stages and primary treatments. Conclusion: An elevated SIRI is negatively associated with worse survival outcomes of gastrointestinal malignancy patients and can be used as a risk stratification index for gastrointestinal malignancies.

Keywords: disease-free survival; gastrointestinal malignancy; inflammatory biomarker; lymphocytes; meta-analysis; monocytes; neutrophils; overall survival; prognostic index; systemic inflammation response index.

Publication types

  • Meta-Analysis

MeSH terms

  • Disease-Free Survival
  • Gastrointestinal Neoplasms*
  • Humans
  • Inflammation
  • Patients
  • Prognosis
  • Retrospective Studies